BRCA2 Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report
Case Reports in Oncology · 14.08.2023 · 621-627
DOI: 10.1159/000531134 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 14.08.2023. Verfasst von Keisuke Okubo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
A 66-year-old male was diagnosed with cT4N0M1b small-cell neuroendocrine carcinoma of the prostate. Four months after the administration of combined androgen blockade, multiple novel metastatic regions in the lung and liver and progression of bone metastasis were observed. The patient was referred to our hospital because of biochemical and radiographic progression after four cycles of docetaxel as a first-line therapy for castration-resistant prostate cancer. Transurethral resection of the prostate and hepatic biopsy revealed small-cell carcinoma with positive expression of neuroendocrine markers. The FoundationOne CDx next-generation sequencing test revealed several pathogenic variants, including BRCA2 (W1692fs*3), KEAP1 (R320W), and TP53 (C2385) mutation. After four cycles of chemotherapy with carboplatin plus etoposide (CE), the metastatic regions regressed markedly. The prostate-specific antigen (PSA) and neuron-specific enolase (NSE) level decreased by 96.9% and 91.6%, respectively. However, 2 months after the completion of four cycles of CE, elevation of tumor marker levels, and re-growth of the metastatic regions were observed. Although olaparib, a poly (ADP-ribose) polymerase inhibitor (PARPi), achieved a 45.2% decrease in NSE, the patient rejected to continue therapy because of G2 adverse events. After receiving an additional two cycles of CE and one cycle of cabazitaxel, the patient died because of cancer progression 24 months after the initial treatment for prostate cancer. Here, we present a case of BRCA2-altered small-cell neuroendocrine prostate cancer treated with both platinum-containing chemotherapy and PARPi. Both therapies achieved an initial response; however, durable responses were not obtained. Additional discussion regarding the optimal treatment strategy for BRCA-altered small-cell/neuroendocrine prostate cancer is required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
- Department of Urology, Akita Red Cross Hospital, Akita, Japan.
- Department of Urology, Omagari Kousei Medical Center, Akita, Japan.
- Pathology, Akita University Hospital, Akita, Japan.
Zitieren
APA
Okubo, K., Narita, S., Koizumi, A., Takahashi, Y., Sagehashi, R., Mori, K., Sobu, R., Sato, H., Kashima, S., Kobayashi, M., Yamamoto, R., Nara, T., Numakura, K., Saito, M., Nanjo, H., & Habuchi, T. (2023). BRCA2 Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report. Case Reports in Oncology, 621-627. https://doi.org/10.1159/000531134
Vancouver
Okubo K, Narita S, Koizumi A, Takahashi Y, Sagehashi R, Mori K, et al. BRCA2 Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report. Case Reports in Oncology. 2023:621-627. doi:10.1159/000531134
BibTeX
@article{Okubo2023,
author = {Okubo, Keisuke and Narita, Shintaro and Koizumi, Atsushi and Takahashi, Yoshiko and Sagehashi, Ryuichiro and Mori, Kanami and Sobu, Ryuta and Sato, Hiromi and Kashima, Soki and Kobayashi, Mizuki and Yamamoto, Ryohei and Nara, Taketoshi and Numakura, Kazuyuki and Saito, Mitsuru and Nanjo, Hiroshi and Habuchi, Tomonori},
title = {BRCA2 Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report},
journal = {Case Reports in Oncology},
year = {2023},
pages = {621--627},
doi = {10.1159/000531134}
}
EUVIMED